Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
BPC-157
Repair & Recovery
Molecular Dossier
- Rank Index: 6
- Status: Pending Reclassification
- What does this mean?
- Molecular Structure: 15 Amino Acid Pentadecapeptide
About BPC-157
Body Protection Compound-157 (BPC-157) is a 15-amino-acid peptide originally identified in and derived from gastric juice protective secretions. On April 22, 2026, BPC-157 was formally removed from the FDA Category 2 restricted list following HHS Secretary Robert F. Kennedy Jr.'s February 2026 announcement that ~14 of 19 restricted peptides would return to legal compounding status. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review BPC-157 at its July 23–24, 2026 meeting to formally restore it to the 503A Category 1 bulks list — a decision that would allow licensed compounding pharmacies to prepare it under physician prescription. Until that ruling, BPC-157 is available strictly as a Research Use Only (RUO) compound for laboratory and academic investigation. BPC-157 has demonstrated broad tissue-repair and anti-inflammatory properties across preclinical and early clinical evidence: oral and parenteral administration show benefits in gastric ulcer healing, intestinal permeability reduction (leaky gut), tendon and ligament repair, muscle strain recovery, and neuroprotection. A 2021 systematic review identified persistent upregulation of growth factors (VEGF, FGF, HGF) and anti-inflammatory cytokine shifts following BPC-157 administration. As of 2026, there are only ~3 completed human studies with fewer than 30 total subjects — most evidence remains preclinical. However, the April 2026 regulatory shift has enabled institutional review boards and research centers to design rigorous Phase 1/2 human trials now underway. Oral bioavailability is surprisingly robust despite peptidic structure. Parenteral routes include subcutaneous, intramuscular, and intradermal injections. Side effects are rare in available human data. Removal from Category 2 does NOT constitute FDA approval but rather legal permission for compounding and clinical research.
BPC-157 (Body Protection Compound-157) is a pentadecapeptide composed of 15 amino acids. It is a partial sequence of the body protection compound (BPC) that is discovered in and isolated from human gastric juice. Clinical research has demonstrated its significant potential in accelerating the healing of various wounds, including tendon-to-bone healing and superior healing of damaged ligaments.
The biological mechanism of BPC-157 is primarily linked to its ability to modulate angiogenesis—the formation of new blood vessels—through the upregulation of Vascular Endothelial Growth Factor (VEGF). This process is critical for tissue regeneration in poorly vascularized areas such as tendons. Furthermore, research indicates its role in promoting the outgrowth of tendon fibroblasts and increasing the expression of growth hormone receptors, which may explain its synergistic effect when paired with GH secretagogues.
In addition to musculoskeletal repair, BPC-157 has shown remarkable gastroprotective properties, maintaining the integrity of the gastrointestinal mucosa and potentially reversing damage caused by NSAIDs or inflammatory conditions. While human clinical trials are ongoing, the established safety profile in animal models suggests a high degree of biological tolerability.
BPC-157: Mechanism of Action Explained
Clinical Focus
Injury Repair & Gut Health
Archival Aliases
Wolverine, Body Protection Compound
Frequently Asked Questions
What is the proper storage protocol for lyophilized peptides?
Lyophilized (freeze-dried) peptides should be stored in a cool, dark place, ideally a freezer at -20°C for long-term stability. Exposure to light, heat, and moisture can lead to degradation. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2°C to 8°C and typically used within 30 days to ensure potency and prevent bacterial growth.
What is the role of bacteriostatic water in peptide research?
Bacteriostatic water is sterile water containing 0.9% benzyl alcohol, which acts as a preservative to inhibit the growth of bacteria. In research settings, it is the standard solvent for reconstituting peptides. Unlike sterile water, which is for single use, bacteriostatic water allows for multiple withdrawals from a vial over several weeks while maintaining a sterile environment.
What is the proposed mechanism for BPC-157 in tissue repair?
BPC-157 (Body Protective Compound) is a pentadecapeptide that promotes angiogenesis—the formation of new blood vessels—via the upregulation of VEGFR2 expression. This increased vascularity facilitates the delivery of nutrients to poorly vascularized tissues like tendons and ligaments, accelerating the natural healing process of the extracellular matrix.
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
How does BPC-157 interact with the growth hormone receptor?
BPC-157 has been observed in laboratory models to increase the expression of growth hormone receptors on fibroblasts. By upregulating these receptors, BPC-157 enhances the effectiveness of natural growth hormone in the localized area of injury, leading to a synergistic effect on tendon and ligament healing that exceeds the capacity of GH alone. Source verification confirms these findings in longitudinal research models.
Does BPC-157 affect the nitric oxide pathway?
Yes, research suggests BPC-157 modulates the nitric oxide (NO) system. It has been shown to induce NO release, which contributes to its cytoprotective effects in the gastric mucosa and its ability to promote angiogenesis. This modulation is a key component of its "Body Protective" nomenclature, as it helps maintain endothelial integrity under stress.
What is the significance of BPC-157 being stable in human gastric juice?
Unlike many peptides that degrade instantly in the stomach, BPC-157 is a fragment of a protein found naturally in human gastric juice. This innate stability allows it to survive the acidic environment of the digestive tract for longer periods, which is why research into its oral bioavailability for inflammatory bowel disease (IBD) is so prominent in current literature.
How long until I feel BPC-157 working for my injury?
Research models report varying timelines; minor inflammatory responses may modulate in days, while structural tissue repair, such as tendon-to-bone re-attachment, typically requires consistent 4-6 week observation windows to document significant cellular remodeling.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | 15 Amino Acid Pentadecapeptide |
| Primary Pathway | Repair & Recovery |
| Research Phase | Pending Reclassification |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-31 10:51:46